19,800 Shares in Pfizer Inc. $PFE Purchased by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. bought a new stake in Pfizer Inc. (NYSE:PFE) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 19,800 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Grey Fox Wealth Advisors LLC bought a new stake in shares of Pfizer during the 3rd quarter worth $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the 2nd quarter valued at approximately $30,000. Darwin Wealth Management LLC acquired a new stake in Pfizer in the second quarter valued at approximately $32,000. Evelyn Partners Asset Management Ltd acquired a new position in shares of Pfizer during the second quarter worth $33,000. Finally, True Wealth Design LLC raised its position in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer launched a Phase 2 study of an mRNA influenza vaccine, advancing its mRNA platform into a large seasonal market — a successful program could drive multi-year upside and higher-margin sales. Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
• Positive Sentiment: Pfizer updated a Phase 1 study for a new obesity injectable — progress in obesity therapeutics targets a very large market and would materially diversify revenue if clinical development continues to advance. Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
• Positive Sentiment: The FDA granted full approval to Pfizer’s BRAFTOVI regimen for first‑line treatment of BRAF V600E-mutant metastatic colorectal cancer (mCRC), converting prior accelerated approval — this expands the label and reduces regulatory risk, supporting near‑term oncology sales. Pfizer Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC
• Positive Sentiment: Income-focused narratives are supporting demand: coverage and write-ups highlighting Pfizer’s attractive dividend (yield cited >6% by some outlets) are drawing investor interest into the stock as a yield play. Love Dividends? 1 Stock to Buy Now With a Yield Over 6%
• Neutral Sentiment: Analysts at Zacks moved Pfizer from “strong sell” to “hold,” which reduces immediate downside narrative but is not a strong buy signal. Zacks upgrade to Hold
• Neutral Sentiment: Recent quarterly results beat EPS and revenue estimates, showing operating resilience despite slight year‑over‑year revenue decline — supports the stock’s valuation but doesn’t eliminate structural concerns.
• Negative Sentiment: RBC Capital initiated coverage with an Underperform and $25 target, warning of a projected $15B–$20B structural revenue decline through 2030 — this report injects a bearish, long‑term revenue risk narrative that can cap upside. RBC Initiates with $25 Target

Pfizer Trading Up 1.9%

Shares of PFE stock opened at $27.61 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The stock has a 50 day simple moving average of $26.13 and a two-hundred day simple moving average of $25.41. The company has a market cap of $156.97 billion, a P/E ratio of 20.30 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.63 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer’s payout ratio is currently 126.47%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a report on Thursday, February 12th. HSBC reaffirmed a “buy” rating and set a $29.00 target price on shares of Pfizer in a report on Wednesday, December 10th. Finally, Morgan Stanley decreased their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $27.70.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.